AK Medical (1789) disclosed a plan to repurchase its shares on the open market pursuant to a general mandate granted at the annual general meeting held on 18 June 2025. According to the announcement, the mandate allows the company to repurchase up to 10% of its issued shares as of the date of the annual general meeting, totaling up to 112,269,577 shares.

AK Medical (1789) stated that it expects to allocate up to HK$150,000,000 from internal financial resources for the proposed share repurchase. All repurchased shares will be canceled upon settlement. The company emphasized that the share repurchase will comply with relevant regulations, including the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, and the Companies Act of the Cayman Islands. The plan will remain in effect until the expiry of the mandate, which includes the conclusion of the next annual general meeting or the date of any revocation or variation of authority by shareholders.

Management indicated that this decision reflects confidence in the group’s outlook and prospects, adding that the company maintains a solid financial position. However, the announcement also highlights that any repurchase activity is subject to market conditions, and no assurance is provided regarding the timing, quantity, or price of repurchases.